Based on the excellent financial results in the first half of 2015 and excellent prospects for the remainder of the year, Fresenius Kabi, the leading supplier of I.V. generic drugs, raises its 2015 earnings guidance.
Fresenius now expects a net income* growth of 18% to 21% in constant currency. Previously, the company expected a net income* growth of 13% to 16% in constant currency. The company fully confirms its group sales guidance. Sales are now expected to increase by 8% to 10% in constant currency (previously: 7% to 10%).
Fresenius Kabi now expects organic sales growth of 6% to 8%. EBIT growth in constant currency is expected to be in the range of 18% to 21%. Previously, Fresenius Kabi projected organic sales growth of 4% to 7% and EBIT growth in constant currency in the range of 11% to 14%.
Cross reference: Picture is available at AP Images (www.apimages.com) and www.presseportal.de/nr/9276
*Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (~€10 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the efficiency program at Fresenius Kabi (~€100 million before tax), and before the disposal gain from the divestment of two HELIOS hospitals (€34 million before tax); 2014 before special items
30 July 2015
